Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Collapse of the Plasmacytoid Dendritic Cells compartment in advanced cutaneous melanomas by components of the tumor cell secretome.

Vescovi R, Monti M, Moratto D, Paolini L, Consoli F, Benerini Gatta L, Melocchi L, Calza S, Chiudinelli M, Rossi G, Bugatti M, Maio M, Fonsatti E, Farisoglio C, Simbolo M, Almici C, Verardi R, Scarpa A, Bergese P, Manganoni A, Facchetti F, Vermi W.

Cancer Immunol Res. 2018 Nov 6. pii: canimm.0141.2018. doi: 10.1158/2326-6066.CIR-18-0141. [Epub ahead of print]

PMID:
30401679
2.

"Cancer Bio-Immunotherapy in Siena": Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8-10, 2015.

Maio M, Bertocci E, Fazio C, Chiarucci C, Cutaia O, Scala E, Giacobini G, Lofiego MF, Fonsatti E, Maccalli C, Nicolay HJ, Parmiani G; NIBIT.

Cancer Immunol Immunother. 2016 Nov;65(11):1423-1431. Epub 2016 Sep 12. No abstract available.

PMID:
27619513
3.

Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study.

Maccalli C, Giannarelli D, Capocefalo F, Pilla L, Fonsatti E, Di Giacomo AM, Parmiani G, Maio M.

Oncoimmunology. 2015 Aug 12;5(2):e1071007. eCollection 2016 Feb.

4.

ICOS Expression as Immunologic Marker in Immune Activating Monoclonal Antibodies.

Danielli R, Cutaia O, Fazio C, Bertocci E, Fonsatti E, Maio M, Calabrò L.

Methods Mol Biol. 2016;1393:133-9. doi: 10.1007/978-1-4939-3338-9_13.

PMID:
27033223
5.

Immunologic correlates in the course of treatment with immunomodulating antibodies.

Weide B, Di Giacomo AM, Fonsatti E, Zitvogel L.

Semin Oncol. 2015 Jun;42(3):448-58. doi: 10.1053/j.seminoncol.2015.02.016. Epub 2015 Feb 13. Review.

PMID:
25965363
6.

"Cancer Bio-Immunotherapy in Siena": Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9-11, 2014.

Maio M, Bertocci E, Pilla L, Fazio C, Chiarucci C, Cutaia O, Fonsatti E, Maccalli C, Parmiani G; NIBIT.

Cancer Immunol Immunother. 2016 Jan;65(1):119-26. doi: 10.1007/s00262-015-1699-z. Epub 2015 May 6. No abstract available.

PMID:
25944004
7.

Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.

Calabrò L, Morra A, Fonsatti E, Cutaia O, Fazio C, Annesi D, Lenoci M, Amato G, Danielli R, Altomonte M, Giannarelli D, Di Giacomo AM, Maio M.

Lancet Respir Med. 2015 Apr;3(4):301-9. doi: 10.1016/S2213-2600(15)00092-2. Epub 2015 Mar 26.

PMID:
25819643
8.

Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study.

Di Giacomo AM, Ascierto PA, Queirolo P, Pilla L, Ridolfi R, Santinami M, Testori A, Simeone E, Guidoboni M, Maurichi A, Orgiano L, Spadola G, Del Vecchio M, Danielli R, Calabrò L, Annesi D, Giannarelli D, Maccalli C, Fonsatti E, Parmiani G, Maio M.

Ann Oncol. 2015 Apr;26(4):798-803. doi: 10.1093/annonc/mdu577. Epub 2014 Dec 23.

PMID:
25538176
9.

"Cancer Bio-Immunotherapy in Siena": Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17-19, 2013.

Maio M, Nicolay HJ, Cutaia O, Fonsatti E, Parmiani G.

Cancer Immunol Immunother. 2015 Jan;64(1):131-5. doi: 10.1007/s00262-014-1577-0. Epub 2014 Jul 4. No abstract available.

PMID:
24993565
10.

Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012.

Maio M, Nicolay HJ, Ascierto PA, Belardelli F, Camerini R, Colombo MP, Queirolo P, Ridolfi R, Russo V, Parisi G, Cutaia O, Fonsatti E, Parmiani G.

Cancer Immunol Immunother. 2013 Dec;62(12):1851-8. doi: 10.1007/s00262-013-1496-5. Epub 2013 Nov 5. No abstract available.

PMID:
24190546
11.

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.

Calabrò L, Morra A, Fonsatti E, Cutaia O, Amato G, Giannarelli D, Di Giacomo AM, Danielli R, Altomonte M, Mutti L, Maio M.

Lancet Oncol. 2013 Oct;14(11):1104-1111. doi: 10.1016/S1470-2045(13)70381-4. Epub 2013 Sep 11.

PMID:
24035405
12.

Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma.

Colombino M, Lissia A, Capone M, De Giorgi V, Massi D, Stanganelli I, Fonsatti E, Maio M, Botti G, Caracò C, Mozzillo N, Ascierto PA, Cossu A, Palmieri G.

J Transl Med. 2013 Aug 29;11:202. doi: 10.1186/1479-5876-11-202.

13.

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme.

Di Giacomo AM, Calabrò L, Danielli R, Fonsatti E, Bertocci E, Pesce I, Fazio C, Cutaia O, Giannarelli D, Miracco C, Biagioli M, Altomonte M, Maio M.

Cancer Immunol Immunother. 2013 Jun;62(6):1021-8. doi: 10.1007/s00262-013-1418-6. Epub 2013 Apr 17.

PMID:
23591982
14.

Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond.

Danielli R, Fonsatti E, Calabrò L, Di Giacomo AM, Maio M.

Ann N Y Acad Sci. 2012 Oct;1270:8-12. doi: 10.1111/j.1749-6632.2012.06757.x. Review.

PMID:
23050811
15.

Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications.

Coral S, Covre A, Nicolay HJ, Parisi G, Rizzo A, Colizzi F, Dalla Santa S, Fonsatti E, Fratta E, Sigalotti L, Maio M.

Br J Cancer. 2012 Sep 25;107(7):1116-24. doi: 10.1038/bjc.2012.361. Epub 2012 Aug 21.

16.

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.

Di Giacomo AM, Ascierto PA, Pilla L, Santinami M, Ferrucci PF, Giannarelli D, Marasco A, Rivoltini L, Simeone E, Nicoletti SV, Fonsatti E, Annesi D, Queirolo P, Testori A, Ridolfi R, Parmiani G, Maio M.

Lancet Oncol. 2012 Sep;13(9):879-86. doi: 10.1016/S1470-2045(12)70324-8. Epub 2012 Aug 13.

PMID:
22894884
17.

Ninth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, Italy, October 19-22, 2011: New perspectives in the immunotherapy of cancer.

Maio M, Nicolay HJ, Ascierto PA, Belardelli F, Camerini R, Colombo MP, Queirolo P, Ridolfi R, Russo V, Parisi G, Fonsatti E, Papamichail M, Parmiani G; NIBIT.

Cancer Immunol Immunother. 2012 Sep;61(9):1599-608. Epub 2012 Jun 27. No abstract available.

PMID:
22736255
18.

BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.

Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi V, Massi D, Fonsatti E, Staibano S, Nappi O, Pagani E, Casula M, Manca A, Sini M, Franco R, Botti G, Caracò C, Mozzillo N, Ascierto PA, Palmieri G.

J Clin Oncol. 2012 Jul 10;30(20):2522-9. doi: 10.1200/JCO.2011.41.2452. Epub 2012 May 21.

PMID:
22614978
19.

Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications.

Calabrò L, Sigalotti L, Fonsatti E, Bertocci E, Di Giacomo AM, Danielli R, Cutaia O, Colizzi F, Covre A, Mutti L, Natali PG, Maio M.

J Cell Physiol. 2011 Oct;226(10):2595-600. doi: 10.1002/jcp.22600.

PMID:
21792917
20.

Eighth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, October 7-9, 2010.

Maio M, Nicolay HJ, Ascierto PA, Belardelli F, Camerini R, Colombo MP, Queirolo P, Ridolfi R, Russo V, Fonsatti E; NIBIT, Parmiani G.

Cancer Immunol Immunother. 2011 Jun;60(6):901-7. doi: 10.1007/s00262-011-1006-6. Epub 2011 Mar 24. No abstract available.

PMID:
21431916
21.

Biology and clinical applications of CD40 in cancer treatment.

Fonsatti E, Maio M, Altomonte M, Hersey P.

Semin Oncol. 2010 Oct;37(5):517-23. doi: 10.1053/j.seminoncol.2010.09.002. Review.

PMID:
21074067
22.

CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893.

Kalbasi A, Fonsatti E, Natali PG, Altomonte M, Bertocci E, Cutaia O, Calabrò L, Chiou M, Tap W, Chmielowski B, Maio M, Ribas A.

J Immunother. 2010 Oct;33(8):810-6. doi: 10.1097/CJI.0b013e3181ee73a7.

PMID:
20842056
23.

Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1-3 October 2009.

Maio M, Nicolay HJ, Ascierto PA, Belardelli F, Camerini R, Colombo MP, Queirolo P, Ridolfi R, Russo V, Fonsatti E, Parmiani G; NIBIT.

Cancer Immunol Immunother. 2010 Dec;59(12):1895-901. doi: 10.1007/s00262-010-0832-2. Epub 2010 Mar 5. No abstract available.

PMID:
20204388
24.

Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma.

Fratta E, Sigalotti L, Colizzi F, Covre A, Nicolay HJ, Danielli R, Fonsatti E, Altomonte M, Calabrò L, Coral S, Maio M.

J Cell Physiol. 2010 May;223(2):352-8. doi: 10.1002/jcp.22040.

PMID:
20127705
25.

Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours.

Fonsatti E, Nicolay HJ, Altomonte M, Covre A, Maio M.

Cardiovasc Res. 2010 Apr 1;86(1):12-9. doi: 10.1093/cvr/cvp332. Epub 2009 Oct 7. Review.

PMID:
19812043
26.

Sixth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, 16-18 October 2008.

Maio M, Nicolay HJ, Ascierto PA, Belardelli F, Camerini R, Colombo MP, Queirolo P, Ridolfi R, Russo V, Fonsatti E, Parmiani G; NIBIT.

Cancer Immunol Immunother. 2010 Jun;59(6):963-9. doi: 10.1007/s00262-009-0696-5. Epub 2009 Mar 28. No abstract available.

PMID:
19330329
27.

The Italian Network for Tumor Biotherapy (NIBIT). Sharing visions, goals and efforts at European level.

Maio M, Fonsatti E, Burigo A, Parmiani G.

Tumori. 2008 Mar-Apr;94(2):179-81.

PMID:
18564604
28.

The Italian Network for Tumor Biotherapy (NIBIT): getting together to push the field forward.

Maio M, Nicolay HJ, Ascierto P, Belardelli F, Camerini R, Colombo MP, Queirolo P, Ridolfi R, Russo V, Anzalone L, Fonsatti E, Parmiani G.

J Transl Med. 2008 Feb 12;6:8. doi: 10.1186/1479-5876-6-8.

29.

Epigenetic remodelling of DNA in cancer.

Lettini AA, Guidoboni M, Fonsatti E, Anzalone L, Cortini E, Maio M.

Histol Histopathol. 2007 Dec;22(12):1413-24. doi: 10.14670/HH-22.1413. Review.

PMID:
17701921
30.

Primary hepatic epithelioid hemangioendothelioma progressively responsive to interferon-alpha: is there room for novel anti-angiogenetic treatments?

Calabrò L, Di Giacomo AM, Altomonte M, Fonsatti E, Mazzei MA, Volterrani L, Miracco C, Maio M.

J Exp Clin Cancer Res. 2007 Mar;26(1):145-50.

PMID:
17550144
31.

Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications.

Fonsatti E, Nicolay HJ, Sigalotti L, Calabrò L, Pezzani L, Colizzi F, Altomonte M, Guidoboni M, Marincola FM, Maio M.

Clin Cancer Res. 2007 Jun 1;13(11):3333-8.

32.

Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.

Sigalotti L, Fratta E, Coral S, Cortini E, Covre A, Nicolay HJ, Anzalone L, Pezzani L, Di Giacomo AM, Fonsatti E, Colizzi F, Altomonte M, Calabrò L, Maio M.

J Cell Physiol. 2007 Aug;212(2):330-44. Review.

PMID:
17458893
33.

The coincidence of chromosome 15 aberrations and beta2-microglobulin gene mutations is causative for the total loss of human leukocyte antigen class I expression in melanoma.

Paschen A, Arens N, Sucker A, Greulich-Bode KM, Fonsatti E, Gloghini A, Striegel S, Schwinn N, Carbone A, Hildenbrand R, Cerwenka A, Maio M, Schadendorf D.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3297-305.

34.

Is it the primetime for endoglin (CD105) in the clinical setting?

Maio M, Altomonte M, Fonsatti E.

Cardiovasc Res. 2006 Mar 1;69(4):781-3. Epub 2006 Jan 31. No abstract available.

PMID:
16448632
35.

Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications.

Coral S, Sigalotti L, Colizzi F, Spessotto A, Nardi G, Cortini E, Pezzani L, Fratta E, Fonsatti E, Di Giacomo AM, Nicotra MR, Natali PG, Altomonte M, Maio M.

J Cell Physiol. 2006 Apr;207(1):58-66.

PMID:
16252259
36.

Epigenetic immunomodulation of hematopoietic malignancies.

Gattei V, Fonsatti E, Sigalotti L, Degan M, Di Giacomo AM, Altomonte M, Calabrò L, Maio M.

Semin Oncol. 2005 Oct;32(5):503-10. Review.

PMID:
16210091
37.

Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine.

Sigalotti L, Fratta E, Coral S, Tanzarella S, Danielli R, Colizzi F, Fonsatti E, Traversari C, Altomonte M, Maio M.

Cancer Res. 2004 Dec 15;64(24):9167-71.

38.

Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: immunotherapeutic implications.

Calabrò L, Fonsatti E, Altomonte M, Pezzani L, Colizzi F, Nanni P, Gattei V, Sigalotti L, Maio M.

J Cell Physiol. 2005 Feb;202(2):474-7.

PMID:
15389591
39.

Optimizing complement-activating antibody-based cancer immunotherapy: a feasible strategy?

Fonsatti E, Di Giacomo AM, Maio M.

J Transl Med. 2004 Jun 25;2(1):21.

40.
41.

Targeting of HLA-DR molecules transduces agonistic functional signals in cutaneous melanoma.

Altomonte M, Visintin A, Tecce R, Leonardi A, Calabro L, Fonsatti E, Pucillo C, Maio M.

J Cell Physiol. 2004 Aug;200(2):272-6.

PMID:
15174097
42.

Emerging role of endoglin (CD105) as a marker of angiogenesis with clinical potential in human malignancies.

Fonsatti E, Sigalotti L, Arslan P, Altomonte M, Maio M.

Curr Cancer Drug Targets. 2003 Dec;3(6):427-32. Review.

PMID:
14683500
43.

Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach?

Altomonte M, Fonsatti E, Visintin A, Maio M.

Oncogene. 2003 Sep 29;22(42):6564-9. Review.

PMID:
14528281
44.

Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels.

Fonsatti E, Altomonte M, Nicotra MR, Natali PG, Maio M.

Oncogene. 2003 Sep 29;22(42):6557-63. Review.

PMID:
14528280
45.

Methylation-regulated expression of HLA class I antigens in melanoma.

Fonsatti E, Sigalotti L, Coral S, Colizzi F, Altomonte M, Maio M.

Int J Cancer. 2003 Jun 20;105(3):430-1; author reply 432-3. No abstract available.

46.

Endoglin (CD105): a target for anti-angiogenetic cancer therapy.

Fonsatti E, Altomonte M, Arslan P, Maio M.

Curr Drug Targets. 2003 May;4(4):291-6. Review.

PMID:
12699349
47.

Differential levels of soluble endoglin (CD105) in myeloid malignancies.

Calabrò L, Fonsatti E, Bellomo G, Alonci A, Colizzi F, Sigalotti L, Altomonte M, Musolino C, Maio M.

J Cell Physiol. 2003 Feb;194(2):171-5.

PMID:
12494455
48.

Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells.

Maio M, Fonsatti E, Lamaj E, Altomonte M, Cattarossi I, Santantonio C, Melani C, Belli F, Arienti F, Colombo MP, Parmiani G.

Cancer Immunol Immunother. 2002 Mar;51(1):9-14. Epub 2001 Dec 18.

PMID:
11845255
49.

Recombinant transmembrane CD59 (CD59-TM) confers complement resistance to GPI-anchored protein defective melanoma cells.

De Nardo C, Fonsatti E, Sigalotti L, Calabrò L, Colizzi F, Cortini E, Coral S, Altomonte M, Maio M.

J Cell Physiol. 2002 Feb;190(2):200-6.

PMID:
11807824
50.

Bioimmunotherapeutic targets on angiogenetic blood vessels in solid malignangies.

Maio M, Altomonte M, Calabro L, Fonsatti E.

Front Biosci. 2001 Jun 1;6:D776-84. Review.

PMID:
11401781

Supplemental Content

Loading ...
Support Center